News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 81
- Sources here
- 22
- Companies here
- 5
Search results
Stored financial headlines
Active search
81 matching headlines
Ticker or company: SBIMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ANAB Cash Flow Statement
This article provides the quarterly and annual cash flow statements for AnaptysBio Inc (ANAB), detailing operating, investing, and financing cash flows from FY2015Q1 to FY2026Q1. It includes specific figures for net income, capital expenditures, and free cash flow, along with year-over-year changes. The document …
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB
HSBC Holdings PLC has acquired a new stake in AnaptysBio, Inc., purchasing 125,717 shares valued at approximately $7.1 million, representing about 0.43% of the company. This comes despite AnaptysBio reporting a larger-than-expected quarterly loss, though revenue exceeded estimates. Analysts maintain a "Moderate Buy" rating …
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million.
AnaptysBio, Inc.'s equity buyback program, which was announced on March 24, 2025, has concluded. The company repurchased 3,444,079 shares, accounting for 11.5% of its equity, at a total cost of $68.63 million. The plan officially expired on March 31, 2026.
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6% - Here's What Happened
AnaptysBio (NASDAQ:ANAB) stock rose 5.6% on Thursday, trading as high as $55.94 with closing near $55.57, though with trading volume significantly lower than average. Analyst sentiment is mixed, leaning positive, with a consensus "Moderate Buy" rating and a price target of $81.82, despite recent …
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
H.C. Wainwright has reiterated its Buy rating for AnaptysBio (ANAB.US) and maintained its target price at $95. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?
AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current price of …
ANAB
main company
Sharemaestro market context
Trend signal active
52 weeks +333.8% · Next-week setup positive 58.7%